Malignant Astrocytoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MLG169 MIFTS: 47	Malignant Astrocytoma Categories: Cancer diseases, Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Malignant Astrocytoma

MalaCards integrated aliases for Malignant Astrocytoma:

Name: Malignant Astrocytoma ¹¹ ⁷⁵ ⁵ ¹⁴

Astrocytoma of Cerebrum ¹¹

Astrocytoma of Brain ¹¹

Cerebral Astrocytoma ¹¹

Astrocytic Tumor ¹¹

Astroglioma ¹¹

Astrocytoma ⁴³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:3069

MeSH ⁴³ D001254

NCIt ⁴⁹ C4951 C60781

SNOMED-CT ⁶⁸ 189914005 99131000119108

UMLS ⁷¹ C0004114 C0750935

Sources

Summaries for Malignant Astrocytoma

Disease Ontology: ¹¹ A malignant glioma that is has material basis in astrocyte cells, a type of star-shaped glial cell, located in the brain and spinal cord.

MalaCards based summary: Malignant Astrocytoma, also known as astrocytoma of cerebrum, is related to anaplastic astrocytoma and idh-mutant anaplastic astrocytoma. An important gene associated with Malignant Astrocytoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are miRNAs involved in DNA damage response and miRNAs involvement in the immune response in sepsis. The drugs Dabrafenib and Tranexamic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone marrow.

Wikipedia: ⁷⁵ Astrocytomas are a type of brain tumor. They originate in a particular kind of glial cells, star-shaped... more...

Sources

Related Diseases for Malignant Astrocytoma

Diseases related to Malignant Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1053)

#	Related Disease	Score	Top Affiliating Genes
1	anaplastic astrocytoma	32.8	TP53 MIR196A1 KDM4C H2AC18 ATRX
2	idh-mutant anaplastic astrocytoma	32.7	KDM4C ATRX
3	mixed oligodendroglioma-astrocytoma	32.3	TP53 ATRX
4	glioblastoma	32.3	TP53 MIR221 MIR21 MIR155 DGCR5 AGAP2-AS1
5	adult astrocytic tumor	32.2	TP53 ATRX
6	glioma susceptibility 1	32.2	TP53 MIR21 DGCR5
7	brain cancer	31.9	TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
8	high grade glioma	31.8	TPT1-AS1 TP53 MIR9-1 MIR338 MIR221 MIR21
9	central nervous system cancer	31.4	TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
10	glioma	31.3	TP53 MIR221 MIR21 MIR17
11	high-grade astrocytoma	31.3	TP53 ATRX
12	retinal cancer	31.2	TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
13	medulloblastoma	31.2	TP53 NEURL1 MIR9-1 MIR221 MIR17 MIR155
14	lung cancer	31.1	TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
15	peripheral nervous system disease	31.1	TP53 MIR9-1 MIR338 MIR21 MIR199A1 MIR196A1
16	respiratory failure	31.1	MIR21 MIR199A1 MIR17 MIR155 MIR142 H2AC18
17	anaplastic oligodendroglioma	31.1	TP53 KDM4C ATRX
18	diffuse astrocytoma	31.1	TP53 KDM4C H2AC18 ATRX
19	demyelinating disease	31.0	MIR9-1 MIR338 MIR21 MIR155 MIR142 MIR124-1
20	leukemia, chronic myeloid	31.0	TP53 MIR9-1 MIR199A1 MIR196A1 MIR17 MIR155
21	toxic encephalopathy	31.0	TP53 MIR9-1 MIR142 MIR124-1 H2AC18
22	parkinson disease, late-onset	31.0	NEDD8 MIR9-1 MIR21 MIR155 MIR142 MIR124-1
23	spinal cord disease	31.0	TP53 MIR9-1 MIR199A1 MIR196A1 MIR155 MIR142
24	myelodysplastic syndrome	31.0	TP53 MIR9-1 MIR221 MIR199A1 MIR17 MIR142
25	focal epilepsy	30.9	MIR9-1 MIR21 MIR142 MIR124-1
26	leukemia, acute myeloid	30.9	TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
27	leukemia, acute lymphoblastic	30.9	TP53 MIR9-1 MIR221 MIR21 MIR199A1 MIR196A1
28	low grade glioma	30.9	TP53 MIR9-1 MIR338 MIR21 MIR199A1 MIR155
29	bone disease	30.9	MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1
30	nervous system disease	30.8	TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
31	myeloma, multiple	30.8	TP53 MIR9-1 MIR221 MIR21 MIR199A1 MIR17
32	immune deficiency disease	30.8	MIR9-1 MIR221 MIR21 MIR199A1 MIR196A1 MIR17
33	lung cancer susceptibility 3	30.8	TP53 MIR9-1 MIR338 MIR21 MIR199A1 MIR196A1
34	melanoma, uveal	30.8	TP53 MIR9-1 MIR199A1 MIR17 MIR142 KDM4C
35	cerebellar disease	30.8	TP53 MIR9-1 KDM4C H2AC18
36	alzheimer disease, familial, 1	30.8	MIR9-1 MIR338 MIR21 MIR199A1 MIR17 MIR142
37	acute promyelocytic leukemia	30.8	TP53 MIR9-1 MIR221 MIR196A1 MIR17 KDM4C
38	renal cell carcinoma, nonpapillary	30.8	TP53 MIR9-1 MIR338 MIR221 MIR21 MIR199A1
39	diffuse midline glioma, h3 k27m-mutant	30.8	TP53 H2AC18 ATRX
40	central nervous system disease	30.8	MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1
41	hematologic cancer	30.8	MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1
42	ovarian cancer	30.8	TP53 MIR9-1 MIR221 MIR21 MIR199A1 MIR196A1
43	brain glioma	30.8	TP53 KDM4C H2AC18 DGCR5 ATRX
44	nasopharyngeal carcinoma	30.8	TP53 MIR9-1 MIR338 MIR21 MIR196A1 MIR17
45	t-cell acute lymphoblastic leukemia	30.8	MIR9-1 MIR17 MIR155 MIR142 KDM4C H2AC18
46	viral infectious disease	30.8	MIR21 MIR199A1 MIR155 H2AC18
47	oral squamous cell carcinoma	30.8	MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1
48	atypical teratoid rhabdoid tumor	30.7	TP53 MIR142 MIR124-1 H2AC18 ATRX
49	cerebrovascular disease	30.7	MIR9-1 MIR221 MIR21 MIR199A1 MIR17 MIR155
50	skin melanoma	30.7	TP53 MIR21 MIR199A1 KDM4C H2AC18

Graphical network of the top 20 diseases related to Malignant Astrocytoma:

Sources

Symptoms & Phenotypes for Malignant Astrocytoma

Sources

Drugs & Therapeutics for Malignant Astrocytoma

Drugs for Malignant Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 262)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dabrafenib

Approved, Investigational

Phase 4

1195765-45-7

44462760

Tranexamic acid

Approved

Phase 3

1197-18-8

5526

Carmustine

Approved, Investigational

Phase 3

154-93-8

2578

Procarbazine

Approved, Investigational

Phase 3

671-16-9

4915

Tioguanine

Approved

Phase 3

154-42-7

2723601

Hydroxyurea

Approved

Phase 3

127-07-1

3657

Vincristine

Approved, Investigational

Phase 3

2068-78-2, 57-22-7

5978

Vinblastine

Approved

Phase 3

865-21-4

241903 13342

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Valproic acid

Approved, Investigational

Phase 3

99-66-1

3121

Eflornithine

Approved, Withdrawn

Phase 3

70052-12-9

3009

Bevacizumab

Approved, Investigational

Phase 2, Phase 3

216974-75-3

135329020

Lomustine

Approved, Investigational

Phase 3

13010-47-4

3950

Fluorouracil

Approved

Phase 2, Phase 3

51-21-8

3385

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 3

133585-56-5, 60-18-4, 556-02-5

1153 6057

Ornithine

Approved, Nutraceutical

Phase 3

3184-13-2, 70-26-8

6262

Semustine

Experimental, Investigational

Phase 3

13909-09-6

5198

Trabedersen

Investigational

Phase 3

925681-61-4

Antifibrinolytic Agents

Phase 3

Hemostatics

Phase 3

Coagulants

Phase 3

Imatinib Mesylate

Phase 3

220127-57-1

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

Anticonvulsants

Phase 3

Psychotropic Drugs

Phase 3

Endothelial Growth Factors

Phase 2, Phase 3

Vaccines

Phase 3

Angiogenesis Inhibitors

Phase 2, Phase 3

Antineoplastic Agents, Immunological

Phase 2, Phase 3

Mitogens

Phase 3

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Romidepsin

Approved, Investigational

Phase 1, Phase 2

128517-07-7

5352062

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Topotecan

Approved, Investigational

Phase 2

123948-87-8, 119413-54-6

60699 60700

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Erlotinib

Approved, Investigational

Phase 1, Phase 2

183319-69-9, 183321-74-6

176870

Lapatinib

Approved, Investigational

Phase 1, Phase 2

231277-92-2, 388082-78-8

208908

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Leflunomide

Approved, Investigational

Phase 2

75706-12-6

3899

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Methotrexate

Approved

Phase 2

1959-05-2, 59-05-2

4112 126941

Aflibercept

Approved

Phase 2

862111-32-8

124490314

Thiotepa

Approved, Investigational

Phase 2

52-24-4

5453

Interventional clinical trials:

(show top 50) (show all 360)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)	Recruiting	NCT03975829	Phase 4	dabrafenib;trametinib
2	A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma	Unknown status	NCT03633552	Phase 3	Temozolomide
3	Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma	Unknown status	NCT01656980	Phase 3	Carmustine
4	A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas	Unknown status	NCT01765088	Phase 3	Temozolomide;α-IFN
5	PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS	Unknown status	NCT01655927	Phase 3	Tranexamic Acid;Placebo: Saline
6	A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)	Completed	NCT00004259	Phase 3	BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
7	Chemotherapy for Progressive Low Grade Astrocytoma in Children Less Than Ten Years Old	Completed	NCT00002944	Phase 3	carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
8	A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma	Completed	NCT00335075	Phase 3	Temozolomide;Semustine
9	A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma	Completed	NCT03722355	Phase 3	Carmustine
10	NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide	Completed	NCT00717210	Phase 3	Temozolomide
11	Radiotherapy for Malignant Astrocytomas in the Elderly	Completed	NCT00430911	Phase 3	Radiotherapy
12	A Randomized, Double-blind, Placebo-controlled Study of Everolimus in the Treatment of Patients With Subependymal Giant Cell Astrocytomas (SEGA) Associated With Tuberous Sclerosis Complex (TSC)	Completed	NCT00789828	Phase 3	Everolimus;Placebo
13	Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma	Completed	NCT00154375	Phase 3	Imatinib mesylate;Hydroxyurea
14	Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem)	Completed	NCT01502241	Phase 3	Temozolomide
15	A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)	Recruiting	NCT04166409	Phase 3	Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
16	A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations	Recruiting	NCT04576117	Phase 3	Selumetinib Sulfate;Vinblastine Sulfate
17	A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment	Recruiting	NCT02629757	Phase 3	β-elemene
18	Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma	Recruiting	NCT01649830	Phase 3	Temozolomide
19	International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013)	Recruiting	NCT03243461	Phase 3	Temozolomide + Valproic Acid
20	A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas	Active, not recruiting	NCT01236560	Phase 2, Phase 3	Temozolomide;Vorinostat
21	A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy	Active, not recruiting	NCT02796261	Phase 3	Eflornithine;Lomustine
22	A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)	Active, not recruiting	NCT00045968	Phase 3	Dendritic cell immunotherapy
23	Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study.	Terminated	NCT00761280	Phase 3	trabedersen;temozolomide;carmustine;lomustine
24	A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma	Terminated	NCT02414165	Phase 2, Phase 3	Toca FC;Lomustine;Temozolomide
25	Treatment Strategy for Low-grade Gliomas	Terminated	NCT00897377	Phase 3	Temozolomide
26	A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma	Withdrawn	NCT04105374	Phase 2, Phase 3	Extended Release Flucytosine;Temozolomide
27	A Phase II Open-Label, Multiple-Dose Study of Intracavitary Administered 131-I-TM-601 in Adult Patients With Recurrent High-Grade Glioma	Unknown status	NCT00114309	Phase 2	131-I-TM-601;131I-TM601
28	Pediatric Low Grade Astrocytoma: Treatment Guidance	Unknown status	NCT00005084	Phase 2
29	A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma	Unknown status	NCT00683761	Phase 1, Phase 2	131I-TM601
30	A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas	Unknown status	NCT02209428	Phase 2	Temozolomide
31	Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas	Unknown status	NCT01721577	Phase 1, Phase 2	AXL1717
32	ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs	Completed	NCT00025675	Phase 2	gefitinib
33	A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors	Completed	NCT00091182	Phase 2	oxaliplatin
34	Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma	Completed	NCT00679354	Phase 2	cilengitide
35	A Phase II Study of R115777 (Zarnestra) (NSC # 702818, IND# 58,359) in Children With Recurrent or Progressive: High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma	Completed	NCT00070525	Phase 2	tipifarnib
36	A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients	Completed	NCT01462695	Phase 2	Sunitinib Malate
37	Phase II Trial of Irinotecan in Children With Refractory Solid Tumors	Completed	NCT00004078	Phase 2	irinotecan hydrochloride
38	Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma	Completed	NCT02942264	Phase 1, Phase 2	Zotiraciclib (TG02);Temozolomide (TMZ)
39	Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients With Recurrent Malignant Glioma	Completed	NCT00112736	Phase 1, Phase 2	erlotinib;temsirolimus
40	A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG)	Completed	NCT01514201	Phase 1, Phase 2	Temozolomide;Veliparib
41	A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas	Completed	NCT00499473	Phase 2	sunitinib malate
42	Phase II Trial of Pre-Irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma)	Completed	NCT00003621	Phase 2	carmustine;cisplatin;etoposide
43	A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage	Completed	NCT00492089	Phase 2	bevacizumab;placebo
44	Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma	Completed	NCT00823459	Phase 2	Everolimus
45	Proton Radiation for Low Grade Gliomas	Completed	NCT01024907	Phase 1, Phase 2
46	Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas	Completed	NCT01051557	Phase 1, Phase 2	Perifosine;Temsirolimus
47	SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma	Completed	NCT00783393	Phase 2	Temozolomide
48	A Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma (Defined for the Purposes of the Protocol as Anaplastic Astrocytoma [AA] or Glioblastoma Multiforme [GBM]) Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma	Completed	NCT00409214	Phase 2	LS11 (talaporfin sodium)
49	Phase II Study Of ZD1839 (NSC 715055) In Newly Diagnosed Patients With Glioblastoma (Grade 4 Astrocytoma)	Completed	NCT00014170	Phase 2	gefitinib
50	A Phase II Open Label Study of SU101 for Patients With Anaplastic Astrocytoma in First Relapse	Completed	NCT00003775	Phase 2	leflunomide

Search NIH Clinical Center for Malignant Astrocytoma

Cochrane evidence based reviews: astrocytoma

Sources

Genetic Tests for Malignant Astrocytoma

Sources

Anatomical Context for Malignant Astrocytoma

Organs/tissues related to Malignant Astrocytoma:

MalaCards : Brain, Spinal Cord, Bone Marrow, Breast, Endothelial, Bone, Cerebellum

Sources

Publications for Malignant Astrocytoma

Articles related to Malignant Astrocytoma:

(show top 50) (show all 1100)

#	Title	Authors	PMID	Year
1	Lateralized overgrowth with vascular malformation caused by a somatic PTPN11 pathogenic variant: Another piece added to the puzzle of mosaic RASopathies. ⁶²	Mussa A...Resta N	35778969	2022
2	Graphene oxide induced dynamic changes of autophagy-lysosome pathway and cell apoptosis via TFEB dysregulation in F98 cells. ⁶²	Dai D...Zhang C	36244172	2022
3	GDNF Promotes Astrocyte Abnormal Proliferation and Migration Through the GFRα1/RET/MAPK/pCREB/LOXL2 Signaling Axis. ⁶²	Wang M...Zhang B	35925441	2022
4	Malignant transformation in low-grade astrocytoma for long-term monitoring. ⁶²	Tunthanathip T	36412420	2022
5	Clinicopathological analysis of secondary retinal vasoproliferative tumor/reactive retinal astrocytic tumor successfully treated by endoresection. ⁶²	Hashimoto I...Ohno-Matsui K	36067444	2022
6	Lateral ventricle pleomorphic xanthoastrocytoma concurrent with Dandy-Walker complex: A case report. ⁶²	Luo TF...Deng SL	36086683	2022
7	The imaging of the hypoxic microenvironment in tumorous tissue using PET/CT and PET/MRI. ⁶²	Ferda J...Mirka H	35926354	2022
8	Circular RNA circPOSTN promotes neovascularization by regulating miR-219a-2-3p/STC1 axis and stimulating the secretion of VEGFA in glioblastoma. ⁶²	Long N...Chu L	35927233	2022
9	GLIPR1 regulates the TIMP1-CD63-ITGB1-AKT signaling pathway in glioma cells and induces malignant transformation of astroglioma. ⁶²	Li F...Jia P	35966296	2022
10	Global variation in young adult central nervous system tumor incidence by region, age, and sex from 1988 to 2012. ⁶²	Sorajja N...Williams LA	35395483	2022
11	Risk Factors Associated with Malignant Transformation of Astrocytoma: Competing Risk Regression Analysis. ⁶²	Tunthanathip T...Kanjanapradit K	35873847	2022
12	The Diagnostic Significance of CXCL13 in M2 Tumor Immune Microenvironment of Human Astrocytoma. ⁶²	Chang SJ...Chai CY	35570844	2022
13	GFAPδ: A Promising Biomarker and Therapeutic Target in Glioblastoma. ⁶²	Radu R...Brehar FM	35372061	2022
14	Molecular Signaling and Transcriptional Regulation of Histamine H1 Receptor Gene. ⁶²	Mizuguchi H...Fukui H	34595742	2022
15	Circular RNA NF1-419 Inhibits Proliferation and Induces Apoptosis by Regulating Lipid Metabolism in Astroglioma Cells. ⁶²	Li R...Chen D	34376137	2022
16	Promising potential of boron compounds against Glioblastoma: In Vitro antioxidant, anti-inflammatory and anticancer studies. ⁶²	Turkez H...Mardinoglu A	34293392	2021
17	Photosensitizer IR700DX-6T- and IR700DX-mbc94-mediated photodynamic therapy markedly elicits anticancer immune responses during treatment of pancreatic cancer. ⁶²	Zhang D...Bai M	34390852	2021
18	Risk Factors Associated with Malignant Transformation of Astrocytoma: Competing Risk Regression Analysis. ⁶²	Tunthanathip T...Kanjanapradit K	35071077	2021
19	Atomic Force Microscope Nanoindentation Analysis of Diffuse Astrocytic Tumor Elasticity: Relation with Tumor Histopathology. ⁶²	Tsitlakidis A...Foroglou N	34572766	2021
20	4-Methoxydalbergione is a potent inhibitor of human astroglioma U87 cells in vitro and in vivo. ⁶²	Li R...Wu J	33311599	2021
21	The histological representativeness of glioblastoma tissue samples. ⁶²	Mikkelsen VE...Torp SH	33085022	2021
22	Plasma lipidome is dysregulated in Alzheimer's disease and is associated with disease risk genes. ⁶²	Liu Y...Braidy N	34092785	2021
23	Systemic Immune Bias Delineates Malignant Astrocytoma Survival Cohorts. ⁶²	Prosniak M...Hooper DC	33685995	2021
24	Zika virus dysregulates the expression of astrocytic genes involved in neurodevelopment. ⁶²	Shereen MA...Wu J	33891593	2021
25	Molecular Mechanism of Vitamin K2 Protection against Amyloid-β-Induced Cytotoxicity. ⁶²	Huang SH...Chen YC	33805625	2021
26	Neuroprotective effect of emodin against Alzheimer's disease via Nrf2 signaling in U251 cells and APP/PS1 mice. ⁶²	Li Z...Fei X	33300068	2021
27	4-Methoxydalbergione Inhibits Bladder Cancer Cell Growth via Inducing Autophagy and Inhibiting Akt/ERK Signaling Pathway. ⁶²	Du H...Li R	35252345	2021
28	Theabrownin Induces Cell Apoptosis and Cell Cycle Arrest of Oligodendroglioma and Astrocytoma in Different Pathways. ⁶²	Fu JY...Zhao XF	33995088	2021
29	Manipulations of Glutathione Metabolism Modulate IP3-Mediated Store-Operated Ca2+ Entry on Astroglioma Cell Line. ⁶²	Mokrane N...Roussel J	34975458	2021
30	The Glutathione Metabolite γ-Glutamyl-Glutamate Partially Activates Glutamate NMDA Receptors in Central Neurons With Higher Efficacy for GluN2B-Containing Receptors. ⁶²	Sebih F...Roussel J	35046818	2021
31	Malignant transformation of pleomorphic xanthoastrocytoma in pregnant patient: Clinical case and ethical dilemma. ⁶²	Marakovic J...Raguz M	34621584	2021
32	Long-term survival of a patient with diffuse midline glioma in the pineal region: A case report and literature review. ⁶²	Ono T...Shimizu H	34992928	2021
33	β2-Adrenergic Receptor Stimulation Upregulates Cx43 Expression on Glioblastoma Multiforme and Olfactory Ensheathing Cells. ⁶²	Hosseindoost S...Hadjighassem M	32506304	2020
34	Low Dose Astaxanthin Treatments Trigger the Hormesis of Human Astroglioma Cells by Up-Regulating the Cyclin-Dependent Kinase and Down-Regulated the Tumor Suppressor Protein P53. ⁶²	Shin J...Oh JW	33086722	2020
35	[Diffuse Astrocytoma with Malignant Progression after Long-term Temozolomide Monotherapy:A Case Report]. ⁶²	Yabana N...Shimizu H	33071231	2020
36	Gamma-Linolenic acid alters migration, proliferation and apoptosis in human and rat glioblastoma cells. ⁶²	Andreoli Miyake J...Colquhoun A	32439412	2020
37	Optic nerve head reactive retinal astrocytic tumor treated with photodynamic therapy. ⁶²	Onishi AC...Fawzi AA	32715158	2020
38	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. ⁶²	Wick A...Wick W	32064499	2020
39	Reactivation of Retinopathy of Prematurity in Adults and Adolescents. ⁶²	Uner OE...Hubbard GB	32224099	2020
40	Beclin1 Binds to Enterovirus 71 3D Protein to Promote the Virus Replication. ⁶²	Xiang Q...Wu J	32674313	2020
41	Spinal cord anaplastic astrocytoma with BRAF V600E mutation: A case report and review of literature. ⁶²	Takamiya S...Yamaguchi S	31986557	2020
42	Clinical significance of CD133 and Nestin in astrocytic tumor: The correlation with pathological grade and survival. ⁶²	Zhang Q...Chen Z	31677196	2020
43	Arsenic trioxide induces gasdermin E mediated pyroptosis in astroglioma cells. ⁶²	Wang J...Min X	35117539	2020
44	The interrupted effect of autophagic flux and lysosomal function induced by graphene oxide in p62-dependent apoptosis of F98 cells. ⁶²	Zhang C...Shao L	32188458	2020
45	MiR-1247-5p Functions as a Tumor Suppressor in Human Astroglioma Cells by Targeting CDC14B. ⁶²	Liu Q...Chen T	32366555	2020
46	Glyphosate-based herbicide impairs energy metabolism and increases autophagy in C6 astroglioma cell line. ⁶²	Neto da Silva K...Glaser V	32085696	2020
47	Nifurtimox Hampered the Progression of Astroglioma In vivo Via Manipulating the AKT-GSK3β axis. ⁶²	Zhang Q...Kong E	32271693	2020
48	Splice-site variant in ACSL5: a marker promoting opposing effect on cell viability and protein expression. ⁶²	Perez-Nunez I...Alcina A	31053784	2019
49	Retinal vasoproliferative tumor (Retinal reactive astrocytic tumor). ⁶²	Crespo Carballes MJ...Quijada Angeli S	31296349	2019
50	Cytotoxic and apoptotic potential of Phyllodium elegans extracts on human cancer cell lines. ⁶²	Jung S...Oh JW	31633448	2019

Sources

Genes for Malignant Astrocytoma

Genes related to Malignant Astrocytoma (2 elite genes):

(show top 50) (show all 141)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	TP53	Tumor Protein P53	Protein Coding	408.96	Pathogenic ⁵ DISEASES inferred ¹⁴
2	ATRX	ATRX Chromatin Remodeler	Protein Coding	407.97	Pathogenic ⁵ DISEASES inferred ¹⁴
3	NEURL1	Neuralized E3 Ubiquitin Protein Ligase 1	Protein Coding	19.5	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Functions (show sections)
4	MIR199A1	MicroRNA 199a-1	RNA Gene	13.63	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
5	AGAP2-AS1	AGAP2 Antisense RNA 1	RNA Gene	13.19	DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)
6	NEDD8	NEDD8 Ubiquitin Like Modifier	Protein Coding	12.84	DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)
7	MIR21	MicroRNA 21	RNA Gene	12.42	DISEASES inferred ¹⁴ ¹⁴
8	TPT1-AS1	TPT1 Antisense RNA 1	RNA Gene	12.2	DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)
9	LINC01198	Long Intergenic Non-Protein Coding RNA 1198	RNA Gene	12.17	DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)
10	MIR9-1	MicroRNA 9-1	RNA Gene	11.84	DISEASES inferred ¹⁴ ¹⁴
11	MIR17	MicroRNA 17	RNA Gene	11.72	DISEASES inferred ¹⁴ ¹⁴
12	H2AC18	H2A Clustered Histone 18	Protein Coding	11.64	DISEASES inferred ¹⁴ ¹⁴
13	MIR155	MicroRNA 155	RNA Gene	10.99	DISEASES inferred ¹⁴ ¹⁴
14	MIR221	MicroRNA 221	RNA Gene	10.89	DISEASES inferred ¹⁴ ¹⁴
15	MIR196A1	MicroRNA 196a-1	RNA Gene	10.86	DISEASES inferred ¹⁴ ¹⁴
16	KDM4C	Lysine Demethylase 4C	Protein Coding	10.74	DISEASES inferred ¹⁴ ¹⁴
17	MIR124-1	MicroRNA 124-1	RNA Gene	10.72	DISEASES inferred ¹⁴ ¹⁴
18	MIR338	MicroRNA 338	RNA Gene	10.66	DISEASES inferred ¹⁴ ¹⁴
19	MIR142	MicroRNA 142	RNA Gene	10.6	DISEASES inferred ¹⁴ ¹⁴
20	DGCR5	DiGeorge Syndrome Critical Region Gene 5	RNA Gene	10.54	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
21	MIR126	MicroRNA 126	RNA Gene	10.52	DISEASES inferred ¹⁴ ¹⁴
22	MIR222	MicroRNA 222	RNA Gene	10.48	DISEASES inferred ¹⁴ ¹⁴
23	MIR330	MicroRNA 330	RNA Gene	10.45	DISEASES inferred ¹⁴ ¹⁴
24	MIR125A	MicroRNA 125a	RNA Gene	10.42	DISEASES inferred ¹⁴ ¹⁴
25	MIR145	MicroRNA 145	RNA Gene	10.4	DISEASES inferred ¹⁴ ¹⁴
26	MIR139	MicroRNA 139	RNA Gene	10.39	DISEASES inferred ¹⁴ ¹⁴
27	MIR10B	MicroRNA 10b	RNA Gene	10.37	DISEASES inferred ¹⁴ ¹⁴
28	MIR143	MicroRNA 143	RNA Gene	10.21	DISEASES inferred ¹⁴ ¹⁴
29	MIR193A	MicroRNA 193a	RNA Gene	10.16	DISEASES inferred ¹⁴ ¹⁴
30	MIR7-1	MicroRNA 7-1	RNA Gene	10.1	DISEASES inferred ¹⁴ ¹⁴
31	MIR34A	MicroRNA 34a	RNA Gene	10.1	DISEASES inferred ¹⁴ ¹⁴
32	MIR30A	MicroRNA 30a	RNA Gene	10.09	DISEASES inferred ¹⁴ ¹⁴
33	MIR19A	MicroRNA 19a	RNA Gene	10.06	DISEASES inferred ¹⁴ ¹⁴
34	MIR214	MicroRNA 214	RNA Gene	10.03	DISEASES inferred ¹⁴ ¹⁴
35	MIR181A1	MicroRNA 181a-1	RNA Gene	9.99	DISEASES inferred ¹⁴ ¹⁴
36	MIR224	MicroRNA 224	RNA Gene	9.96	DISEASES inferred ¹⁴ ¹⁴
37	MIR93	MicroRNA 93	RNA Gene	9.91	DISEASES inferred ¹⁴ ¹⁴
38	MIR296	MicroRNA 296	RNA Gene	9.9	DISEASES inferred ¹⁴ ¹⁴
39	MIR204	MicroRNA 204	RNA Gene	9.84	DISEASES inferred ¹⁴ ¹⁴
40	MIR10A	MicroRNA 10a	RNA Gene	9.83	DISEASES inferred ¹⁴ ¹⁴
41	MIR23A	MicroRNA 23a	RNA Gene	9.79	DISEASES inferred ¹⁴ ¹⁴
42	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	9.79	DISEASES inferred ¹⁴ ¹⁴
43	MIR144	MicroRNA 144	RNA Gene	9.74	DISEASES inferred ¹⁴ ¹⁴
44	MIR205	MicroRNA 205	RNA Gene	9.73	DISEASES inferred ¹⁴ ¹⁴
45	MIR223	MicroRNA 223	RNA Gene	9.73	DISEASES inferred ¹⁴ ¹⁴
46	MIR376A1	MicroRNA 376a-1	RNA Gene	9.71	DISEASES inferred ¹⁴ ¹⁴
47	MIR29B1	MicroRNA 29b-1	RNA Gene	9.7	DISEASES inferred ¹⁴ ¹⁴
48	MIR140	MicroRNA 140	RNA Gene	9.69	DISEASES inferred ¹⁴ ¹⁴
49	MIRLET7A1	MicroRNA Let-7a-1	RNA Gene	9.68	DISEASES inferred ¹⁴ ¹⁴
50	MIR22	MicroRNA 22	RNA Gene	9.68	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Malignant Astrocytoma

ClinVar genetic disease variations for Malignant Astrocytoma:

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	TP53	NM_000546.6(TP53):c.733G>A (p.Gly245Ser)	SNV	Pathogenic	12365	rs28934575	GRCh37: 17:7577548-7577548 GRCh38: 17:7674230-7674230
2	ATRX	NM_000489.6(ATRX):c.5579A>G (p.Asn1860Ser)	SNV	Pathogenic	11724	rs45439799	GRCh37: X:76856021-76856021 GRCh38: X:77600552-77600552
3	TP53	NM_000546.6(TP53):c.844C>T (p.Arg282Trp)	SNV	Pathogenic	12364	rs28934574	GRCh37: 17:7577094-7577094 GRCh38: 17:7673776-7673776

Sources

Expression for Malignant Astrocytoma

Search GEO for disease gene expression data for Malignant Astrocytoma.

Sources

Pathways for Malignant Astrocytoma

Pathways related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	miRNAs involved in DNA damage response ⁷⁴	11.28	TP53 MIR221 MIR21 MIR17
2	miRNAs involvement in the immune response in sepsis ⁷⁴	11.05	MIR9-1 MIR21 MIR199A1 MIR155
3	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	10.92	MIR9-1 MIR221 MIR199A1 MIR17 MIR155

Sources

GO Terms for Malignant Astrocytoma

Cellular components related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.62	MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1

Biological processes related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	9.63	MIR221 MIR21 MIR17
2	miRNA-mediated gene silencing	GO:0035195	9.58	MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1
3	negative regulation of cell migration involved in sprouting angiogenesis	GO:0090051	9.5	MIR221 MIR199A1 MIR196A1
4	negative regulation of gene expression	GO:0010629	9.5	MIR155 MIR17 MIR199A1 MIR21 MIR338 MIR9-1
5	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.46	MIR9-1 MIR221 MIR21 MIR17
6	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.43	MIR199A1 MIR17
7	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.4	MIR21 MIR17
8	positive regulation of metalloendopeptidase activity	GO:1904685	9.37	MIR21 MIR17
9	negative regulation of interleukin-21 production	GO:0032705	9.26	MIR221 MIR21

Molecular functions related to Malignant Astrocytoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.61	TP53 MIR9-1 MIR338 MIR21 MIR199A1 MIR17
2	mRNA base-pairing translational repressor activity	GO:1903231	9.28	MIR9-1 MIR338 MIR221 MIR21 MIR199A1 MIR196A1